NDA 208712 · Sobi
Vonjo
Pacritinib Citrate · Oral · Kinase Inhibitor
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 28, 2022: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Feb 28, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
52
3 Phase 3, 18 recruiting
FAERS reports
3,069
1,125 serious, 350 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 30, 2026.
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L ( 1 ). This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin 1 receptor associated kinase-1 (IRAK1) which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Pacritinib is also an inhibitor of activin A receptor, type 1/activin receptor like-kinase 2 (ACVR1/ALK2). MF is often associated with dysregulated JAK2 signaling. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib has...
Therapeutic areas: Oncology · Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterReviewLabel
1 products under this application
- VONJO · PACRITINIB CITRATE EQ 100MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pacritinib" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisPivotal-lookingActive, not recruiting
Swedish Orphan BiovitrumIndustry
NCT03165734 · 407 participants · Start Jun 26, 2017 · Primary completion Oct 5, 2026
Drug: Pacritinib; Physician's Choice medications · For: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 207 sites in all
- Pacritinib Versus Best Available Therapy to Treat MyelofibrosisPivotal-lookingTerminated
CTI BioPharmaIndustry
NCT01773187 · 327 participants · Start Jan 2013 · Primary completion Jan 2015
Drug: Pacritinib; Best Available Therapy · For: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Sites: Scottsdale, Arizona; Omaha, Nebraska; Morristown, New Jersey · 81 sites in all
- Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaPivotal-lookingTerminated
CTI BioPharmaIndustry
NCT02055781 · 311 participants · Start Feb 2014 · Primary completion Apr 2016
Drug: Pacritinib; Best Available Therapy · For: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Sites: Scottsdale, Arizona; Tucson, Arizona; Duarte, California · 122 sites in all
- PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerPivotal-lookingTerminated
CTI BioPharmaIndustry
NCT04404361 · 200 participants · Start May 22, 2020 · Primary completion Sep 21, 2021
Drug: Pacritinib; Placebo · For: COVID19; COVID-19; COVID
Sites: Orange, California; Jacksonville, Florida; Atlanta, Georgia · 21 sites in all
CTI BioPharmaIndustry
NCT04884191 · 165 participants · Start Jul 31, 2017 · Primary completion Sep 4, 2019
Drug: Pacritinib · For: Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post- Essential Thrombocythemia Myelofibrosis
Sites: Phoenix, Arizona; Duarte, California; Los Angeles, California · 62 sites in all
National Cancer Institute (NCI)NIH
NCT06303193 · 160 participants (planned) · Start Nov 24, 2026 · Primary completion Jan 1, 2030
Drug: pacritinib · For: Myelodysplastic Syndromes
Sites: Bethesda, Maryland
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Pivotal-lookingRecruiting
Swedish Orphan BiovitrumIndustry
NCT06782373 · 156 participants (planned) · Start May 28, 2025 · Primary completion Oct 30, 2028
Drug: Pacritinib; Placebo · For: VEXAS; VEXAS Syndrome
Sites: Scottsdale, Arizona; Boston, Massachusetts; Rochester, Minnesota · 39 sites in all
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT04858256 · 100 participants (planned) · Start Mar 29, 2023 · Primary completion Nov 2027
Drug: Pacritinib · For: T-Cell Neoplasm; Lymphoproliferative Disorders
Sites: Duarte, California; Tampa, Florida; Ann Arbor, Michigan · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea651
- off label use623
- fatigue388
- product dose omission issue337
- death314
- nausea304
- platelet count decreased297
- haemoglobin decreased213
- asthenia158
- dizziness132
- drug ineffective119
- splenomegaly109
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 9 |
| 2022 | 421 |
| 2023 | 1,102 |
| 2024 | 750 |
| 2025 | 493 |
| 2026 | 288 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vonjo (Pacritinib Citrate)
2024 spending
$111M
Beneficiaries
1,046
5,065 claims
Per beneficiary
$105,945
$210.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $37,696,367 |
| 2023 | $92,544,883 |
| 2024 | $110,818,538 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, et al. · JAMA Oncol 2018 · Randomized Controlled Trial
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, et al. · Lancet Haematol 2017 · Clinical Trial, Phase III, Comparative Study
- Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D, Mesa R, Scott B, et al. · Blood Adv 2020 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE, Mesa RA · Future Oncol 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
Pidala J, Holtan SG, Walton K, et al. · Blood 2024 · Clinical Trial, Phase II
- Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D, Hoffman R · Expert Opin Emerg Drugs 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Sobi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.